CME Group Inc. has been upgraded today by the securities research analysts at investment firm UBS which increased CME Group from a “neutral” rating to “buy.” UBS noted with their buy rating that CME Group’s diversified product portfolio could benefit via continued recovery of the economy and therefore, higher interest rates in the following year, 2012. UBS did not adjust their price target for ‘CME’ and remains fixed at $318 dollars. CME is currently trending north during the intraday trading session for a second day in a row. CME had previously been on a downtrend for four days prior to recent gains.
CME Group is slated to release their next earnings report on July 28th, 2011 and the current consensus EPS estimate is expected to be $4.16. CME’s last earnings report was released on April 28th, 2011, and announced EPS of $4.36 with revenue totaling $832 million which was up 20.1 % year to year. CME is currently trading below its 50 & 200-day moving averages and 2011 is currently a down year for the company.
CME Group Inc. offers a wide range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, metals, weather and real estate. The company has market capitalization of $17,987,235,230 and 67,049,0000 shares outstanding. CME has a 52-week high of $328 with the low being $234.50 dollars.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.